AU2005292033A1 - Treatment method - Google Patents

Treatment method Download PDF

Info

Publication number
AU2005292033A1
AU2005292033A1 AU2005292033A AU2005292033A AU2005292033A1 AU 2005292033 A1 AU2005292033 A1 AU 2005292033A1 AU 2005292033 A AU2005292033 A AU 2005292033A AU 2005292033 A AU2005292033 A AU 2005292033A AU 2005292033 A1 AU2005292033 A1 AU 2005292033A1
Authority
AU
Australia
Prior art keywords
mtor inhibitor
administered
aml
therapy
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005292033A
Other languages
English (en)
Inventor
Camille L. Bedrosian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Ariad Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharmaceuticals Inc filed Critical Ariad Pharmaceuticals Inc
Publication of AU2005292033A1 publication Critical patent/AU2005292033A1/en
Assigned to ARIAD PHARMACEUTICALS, INC. reassignment ARIAD PHARMACEUTICALS, INC. Request for Assignment Assignors: ARIAD GENE THERAPEUTICS, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2005292033A 2004-09-30 2005-09-30 Treatment method Abandoned AU2005292033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61548504P 2004-09-30 2004-09-30
US60/615,485 2004-09-30
PCT/US2005/035047 WO2006039414A2 (en) 2004-09-30 2005-09-30 Treatment method

Publications (1)

Publication Number Publication Date
AU2005292033A1 true AU2005292033A1 (en) 2006-04-13

Family

ID=36143059

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005292033A Abandoned AU2005292033A1 (en) 2004-09-30 2005-09-30 Treatment method

Country Status (7)

Country Link
US (1) US20080081053A1 (https=)
EP (1) EP1809276A4 (https=)
JP (1) JP2008514721A (https=)
AU (1) AU2005292033A1 (https=)
CA (1) CA2581372A1 (https=)
MX (1) MX2007003790A (https=)
WO (1) WO2006039414A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
CA2629714A1 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
WO2007143212A1 (en) * 2006-06-02 2007-12-13 Ariad Gene Therapeutics, Inc. Capecitabine combination therapy
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
CN103330694A (zh) * 2006-11-14 2013-10-02 阿里亚德医药股份有限公司 口服制剂
TWI597061B (zh) * 2013-02-20 2017-09-01 國鼎生物科技股份有限公司 治療白血病之方法及組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118677A (en) * 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US7041654B2 (en) * 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
JP4547911B2 (ja) * 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
AU2003247483A1 (en) * 2002-05-30 2003-12-31 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
AU2003248813A1 (en) * 2002-07-05 2004-01-23 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms

Also Published As

Publication number Publication date
WO2006039414A3 (en) 2006-07-06
JP2008514721A (ja) 2008-05-08
CA2581372A1 (en) 2006-04-13
EP1809276A2 (en) 2007-07-25
EP1809276A4 (en) 2009-06-17
WO2006039414A2 (en) 2006-04-13
MX2007003790A (es) 2007-05-24
US20080081053A1 (en) 2008-04-03

Similar Documents

Publication Publication Date Title
Slevin et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer.
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
EP3821887B1 (en) Use of mitoxantrone liposome for treating non-hodgkin's lymphoma
ES2946179T3 (es) Efectos antineoplásicos de inhibidores de JAK2 en combinación con derivados de talidomida y glucocorticoides
AU2013208649B2 (en) Combination therapy for the treatment of cancer
JP6294459B2 (ja) 骨髄性白血病の処置方法
Halle et al. Successful extracorporeal photochemotherapy for chronic graft-versus-host disease in pediatric patients
US20080081053A1 (en) Treatment Method
Gelmon et al. A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Lee et al. Diaziquone given as a continuous infusion is an active agent for relapsed adult acute nonlymphocytic leukemia
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs
WO2015153820A1 (en) Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
JP2026506073A (ja) エフロルニチンを使用する組成物および方法
Jara-Sánchez et al. Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
Jones et al. A randomised phase II study of carmustine alone or in combination with tomour necrosis factor in patients with advanced melanoma
JP4020256B2 (ja) 前立腺癌の局所治療剤
EP3570849B1 (en) Pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
CN1901906A (zh) 治疗套细胞淋巴瘤的cci－779
AU2011202637A1 (en) Composition and methods for treating myelodysplastic syndrome
JP2025516925A (ja) 再発がんを前治療する方法
WO2024257051A1 (en) Compositions, systems, and methods for treating cancer using tumor treating fields (ttfields) and thioredoxin/glutathione inhibitors
KR20050116166A (ko) 이리노테칸의 저항성 유방암 치료용 용도
HK40044845B (en) Use of mitoxantrone liposome for treating non-hodgkin’s lymphoma
KR20220082862A (ko) 혈액 악성 종양을 치료하기 위한 병용 요법
HK40044845A (en) Use of mitoxantrone liposome for treating non-hodgkin’s lymphoma

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ARIAD PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): ARIAD GENE THERAPEUTICS, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted